View Older Stories View More Recent Stories

Feb 4, 2021 06:30AM Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Feb 3, 2021 06:59AM Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Feb 2, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla
Feb 2, 2021 06:59AM WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
Feb 2, 2021 06:59AM Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Feb 1, 2021 07:10AM Bristol-Myers Squibb (BMY) Application for Zeposia for Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by FDA
Feb 1, 2021 06:59AM Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
Jan 22, 2021 01:34PM Bristol-Myers Squibb (BMY) Reports FDA Approval for OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) as First-line Treatment for Patients with Advanced RCC
Jan 22, 2021 01:18PM U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
Jan 21, 2021 06:59AM Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)
Jan 20, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
Jan 20, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Jun
Jan 20, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
Jan 11, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces $2 Billion Additional Share Repurchase Authorization
Jan 11, 2021 06:59AM Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
Jan 11, 2021 01:00AM Press news Biocartis Group NV: BIOCARTIS MEETS 2020 KEY OBJECTIVES
Jan 5, 2021 01:50AM Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb
Jan 4, 2021 07:00AM Bristol Myers Squibb (BMY) Announces EMA Validates its Application for Opdivo as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Jan 4, 2021 06:59AM Bristol Myers Squibb to Present at J.P. Morgan’s 39th Annual Virtual Healthcare Conference
Jan 4, 2021 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Juncti
Jan 4, 2021 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradioth
Jan 1, 2021 06:59AM Bristol Myers Squibb Provides Update on Status of Contingent Value Rights
Dec 28, 2020 07:00AM Bristol-Myers Squibb (BMY) Reports EMA Validation of Marketing Authorization Application for Zeposia (ozanimod)
Dec 28, 2020 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis
Dec 23, 2020 07:02AM Bristol-Myers Squibb (BMY) Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme Will Not Meet Primary Endpoint
Dec 23, 2020 06:59AM Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
Dec 21, 2020 06:59AM Bristol Myers Squibb to Announce Results for Fourth Quarter 2020 on February 4, 2021
Dec 16, 2020 06:59AM Bristol Myers Squibb Strengthens its Commitment to the Environment with New Corporate Goals
Dec 11, 2020 08:03AM Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
Dec 11, 2020 07:15AM Bristol Myers Squibb (BMY) Receives Positive CHMP Opinion for Inrebic for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Dec 11, 2020 07:15AM Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Dec 11, 2020 06:59AM Bristol-Myers Squibb (BMY) Announces Settlement of U.S. Patent Litigation for REVLIMID with Cipla
Dec 11, 2020 06:59AM Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with Cipla
Dec 10, 2020 04:16PM Bristol Myers Squibb Announces Dividend Increase
Dec 8, 2020 07:05AM Checkmate Pharmaceuticals (CMPI) Announces Clinical Collaboration with Bristol Myers Squibb (BMY) to Evaluate CMP-001 in Combination with Nivolumab
Dec 8, 2020 07:00AM Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
Dec 8, 2020 07:00AM Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
Dec 8, 2020 06:59AM Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
Dec 7, 2020 04:30PM Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission
Dec 7, 2020 10:00AM Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020
Dec 5, 2020 12:30PM Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020
Nov 24, 2020 06:59AM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Nov 24, 2020 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Nov 23, 2020 06:31AM Schrodinger Inc. (SDGR) Announces Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb (BMY)
Nov 23, 2020 06:30AM Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb
Nov 17, 2020 08:31AM Bristol-Myers Squibb (BMY) Completes Acquisition of MyoKardia (MYOK)
Nov 17, 2020 08:30AM Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
Nov 17, 2020 07:03AM Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market
Nov 17, 2020 02:03AM Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market Engagement
Nov 16, 2020 04:24PM Bristol-Myers Squibb (BMY) Provides Regulatory Update on Lisocabtagene Maraleucel
View More Recent Stories View Older Stories